Study S000785

Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Type 2 Diabetes - a Dose Finding Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06326047
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 299
Start: 2024-03-18
Primary completion: 2025-09-19
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:NNC0519-0130; DRUG:Placebo; DRUG:Trizepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1291-9196; REGISTRY:jRCT2031230704

Registered primary outcomes

Change in Glycated haemoglobin (HbA1c) [From baseline (week 0) to 12 weeks on a given maintenance dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.